{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:21:52Z","timestamp":1767921712435,"version":"3.49.0"},"reference-count":46,"publisher":"Oncology Nursing Society (ONS)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2013,2,1]]},"DOI":"10.1188\/13.cjon.e13-e20","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T21:03:39Z","timestamp":1359666219000},"page":"E13-E20","source":"Crossref","is-referenced-by-count":12,"title":["Treating Chronic Myeloid Leukemia"],"prefix":"10.1188","volume":"17","author":[{"given":"Cheryl-Anne","family":"Simoneau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2013,1,31]]},"reference":[{"key":"1","unstructured":"American Cancer Society. (2012). Fatigue in people with cancer.<\/i> Retrieved from http:\/\/www.cancer.org\/acs\/groups\/cid\/documents\/webcontent\/002842-pdf.pdf<\/a>"},{"key":"2","unstructured":"Ariad Pharmaceuticals Inc. (2012). Iclusig\u00ae (ponatinib)<\/i> [Package insert]. Retrieved from http:\/\/iclusig.com\/pi\/pdfs\/Iclusig-Prescribing-Information.pdf<\/a>"},{"key":"3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1365-2796.2008.02010.x","article-title":"Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: Enhanced efficacy by enhanced compliance","volume":"264","author":"S. Boonen","year":"2008","journal-title":"Journal of Internal Medicine"},{"key":"4","doi-asserted-by":"publisher","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","article-title":"BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than five years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria","volume":"13","author":"S. Branford","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"5","unstructured":"Bristol-Myers Squibb. (2011). Sprycel\u00ae (dasatinib)<\/i> [Package insert]. Retrieved from http:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf<\/a>"},{"key":"6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: A retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"T. Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"7","article-title":"International Randomized Study of Interferon versus STI571 (IRIS) eight-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [Abstract 1126]","author":"M. Deininger","year":"2009","journal-title":"Blood"},{"key":"8","article-title":"Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia","author":"A. Gater","year":"2012","journal-title":"Leukemia Research"},{"key":"9","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"J. Goldman","year":"2007","journal-title":"Blood"},{"key":"10","article-title":"Dasatinib (versus imatinib) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Analysis of safety and efficacy by use of baseline medications in the DASISION trial [Abstract 2295]","author":"F. Guilhot","year":"2010","journal-title":"Blood"},{"key":"11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.clml.2011.10.004","article-title":"Managing chronic myeloid leukemia","volume":"12","author":"S. Holloway","year":"2012","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"12","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"H. Kantarjian","year":"2009","journal-title":"Blood"},{"key":"13","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"H. Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"14","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"H. Kantarjian","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"15","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"H. Kantarjian","year":"2006","journal-title":"Annals of Internal Medicine"},{"key":"16","article-title":"Ponatinib in the treatment of chronic myeloid leukemia and chromosone-positive acute lymphoblastic leukemia: Review of efficacy and management of side effects","author":"M. Liboon","year":"2012"},{"key":"17","article-title":"Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: Interim analysis of the STIM trial [Abstract 7084]","author":"F. Mahon","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"18","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least two years: The prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"F. Mahon","year":"2010","journal-title":"Lancet Oncology"},{"key":"19","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"D. Marin","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at three months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"D. Marin","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"21","article-title":"Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [Abstract 7009]","author":"M. Mauro","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"22","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s12032-011-9926-8","article-title":"Patient counseling program to improve compliance to imatinib in chronic myeloid leukemia patients","volume":"29","author":"J. Moon","year":"2012","journal-title":"Medical Oncology"},{"key":"23","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study","volume":"113","author":"L. Noens","year":"2009","journal-title":"Blood"},{"key":"24","unstructured":"Novartis Pharmaceuticals. (2012a). Gleevec<\/i>\u00ae (imatinib)<\/i> [Package insert]. Retrieved from http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gleevec_tabs.pdf<\/a>"},{"key":"25","unstructured":"Novartis Pharmaceuticals. (2012b). Tasigna<\/i>\u00ae (nilotinib)<\/i> [Package insert]. Retrieved from http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/tasigna.pdf<\/a>"},{"key":"26","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase myeloid leukemia","volume":"348","author":"S. O'Brien","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"L. Osterberg","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"28","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","article-title":"Adherence to therapy with oral antineoplastic agents","volume":"94","author":"A. Partridge","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"key":"29","unstructured":"Pfizer Inc. (2012). Bosulif\u00ae (bosutinib) [Package insert]. Retrieved from http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=884<\/a>"},{"key":"30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1586\/14737140.4.1.85","article-title":"Clinical and epidemiologic burden of chronic myelogenous leukemia","volume":"4","author":"A. Redaelli","year":"2004","journal-title":"Expert Review of Anticancer Therapy"},{"key":"31","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2165\/00019053-200826050-00007","article-title":"Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia","volume":"26","author":"S. Reed","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"L. Remsing Rix","year":"2009","journal-title":"Leukemia"},{"key":"33","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/sj.leu.2403821","article-title":"A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors","volume":"19","author":"M. Robin","year":"2005","journal-title":"Leukemia"},{"key":"34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"P. Rousselot","year":"2007","journal-title":"Blood"},{"key":"35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3322\/caac.20004","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"K. Ruddy","year":"2009","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"36","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1002\/cncr.25123","article-title":"Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after two years of follow-up in a phase 3 study","volume":"116","author":"G. Saglio","year":"2010","journal-title":"Cancer"},{"key":"37","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"G. Saglio","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"38","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM19990429 3401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"C. Sawyers","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.V104.11.1.1","article-title":"Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC\/ABL kinase inhibitor BMS-354825: Results from a phase I dose escalation study [Abstract 1]","volume":"104","author":"C. Sawyers","year":"2004","journal-title":"Blood"},{"key":"40","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2009.011452","article-title":"Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib","volume":"95","author":"N. Shah","year":"2010","journal-title":"Haematologica"},{"key":"41","article-title":"Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia [Abstract 2209]","author":"M. St. Charles","year":"2009","journal-title":"Blood"},{"key":"42","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"M. Talpaz","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"43","article-title":"Prescription compliance and persistence in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM) [Abstract 6119]","author":"J. Tsang","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"44","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1309\/AJCPUN89CXERVOVH","article-title":"Chronic myelogenous leukemia, BCR-ABL1+","volume":"132","author":"J. Vardiman","year":"2009","journal-title":"American Journal of Clinical Pathology"},{"key":"45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"E. Wu","year":"2010","journal-title":"Current Medical Research and Opinion"},{"key":"46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1185\/03007995.2011.649849","article-title":"Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia","volume":"28","author":"M. Yood","year":"2012","journal-title":"Current Medical Research and Opinion"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/Q58372H563V70368.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:54:48Z","timestamp":1763754888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/17\/1\/treating-chronic-myeloid-leukemia"}},"subtitle":["Improving Management Through Understanding of the Patient Experience"],"short-title":[],"issued":{"date-parts":[[2013,1,31]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2,1]]}},"alternative-id":["Q58372H563V70368"],"URL":"https:\/\/doi.org\/10.1188\/13.cjon.e13-e20","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,31]]}}}